2016


To access this material please log in or register

Register Authorize
2016/№6

Type 2 myocardial infarction: Solved and unsolved issues

Zharsky S. L.
State Budgetary Educational Institution, "Far-East State Medical University" of the Ministry of Health of the Russian Federation, Muravjeva-Amurskogo 35, Khabarovsk 680000

Keywords: type-2 myocardial infarction, acute coronary syndrome, trimetazidine

DOI: 10.18087/rhj.2016.6.2285

The article provides characteristics of type 2 MI. Based on current reports, the author presents information about the prevalence and pathogenesis of type 2 MI as well as about diseases and clinical conditions underlying oxygen and energy imbalance, which results in myocardial necrosis. Also, this review characterizes the clinical course and outcomes of type 2 MI compared to type 1 MI; touches upon issues of diagnostics and therapeutic tactics; and discusses a possibility of using myocardial cytoprotection with trimetazidine.
  1. Thygesen K, Alpert JS, Jaffe AS, Simoons ML, Chaitman BR, White HD et al. Third universal definition of myocardial infarction. Eur Heart J. 2012 Oct;33 (20):2551–67.
  2. Thygesen K, Alpert JS, White HD. Universal definition of myocardial infarction. Eur Heart J. 2007 Oct;28 (20):2525–38.
  3. Alpert JS, Thygesen KA, White HD, Jaffe AS. Diagnostic and therapeutic implications of type 2 myocardial infarction: review and commentary. Am J Med. 2014 Feb;127 (2):105–8.
  4. Желнов В.В., Дятлов Н.В., Дворецкий Л.И. Инфаркт миокарда второго типа. Миф или реальность? Архивъ внутренней медицины. 2016;6 (2):34–41 [Zhelnov V.V., Dyatlov N.V., Dvoreczkij L.I. Infarkt miokarda vtorogo tipa. Mif ili real`nost`? Arxiv`` vnutrennej medicziny`. 2016;6 (2):34–41].
  5. Sandoval Y, Smith SW, Thordsen SE, Apple FS. Supply/demand type 2 myocardial infarction. should we be paying more attention? J Am Coll Cardiol. 2014 May 27;63 (20):2079–87.
  6. Baron T, Hambraeus K, Sundström J, Erlinge D, Jernberg T, Lindahl B. Type 2 myocardial infarction in clinical practice. Heart. 2015 Jan;101 (2):101–6.
  7. Melberg T, Burman R , Dickstein K. The impact of the 2007 ESCACC-AHA-WHF Universal definition on the incidence and classification of acute myocardial infarction: a retrospective cohort study. Int J Cardiol. 2010 Mar 18;139 (3):228–33.
  8. Szymański FM, Karpiński G, Płatek AE, Majstrak F, Hrynkiewicz-Szymacska A, Kotkowski M et al. Clinical characteristics, aetiology and occurrence of type 2 acute myocardial infarction. Kardiol Pol. 2014;72 (4):339–44.
  9. Stein GY, Herscovici G, Korenfeld R , Matetzky S, Gottlieb S, Alon D et al. Type-II myocardial infarction – patient characteristics, management and outcomes. PLoS One. 2014 Jan 2;9 (1):e84285.
  10. Saaby L, Poulsen TS, Hosbond S, Larsen TB, Diederichsen AC, Hallas J et al. Classification of myocardial infarction: frequency and features of type 2 myocardial infarction. Am J Med. 2013 Sep;126 (9):789–97.
  11. Collinson P, Lindahl B. Type 2 myocardial infarction: the chimaera of cardiology? Heart. 2015 Nov;101 (21):1697–703.
  12. El-Haddad H, Robinson E, Swett K, Wells GL. Prognostic implications of type 2 myocardial infarctions. World J Cardiovasc Dis. 2012;2 (4):237–41.
  13. Smilowitz N, Weiss MC, Mahajan AM, Dugan K, Mauricio R, Naoulou B et al. Type 2 myocardial infarction: an observational study of provoking conditions, management and in-hospital outcomes. Circulation. 2014 Nov 25;130 (Suppl 2):A12250.
  14. Landesberg G, Beattie WS, Mosseri M, Jaffe AS, Alpert JS. Perioperative myocardial infarction. Circulation. 2009 Jun 9;119 (22):2936–44.
  15. Hanson I, Kahn J, Dixon S, Goldstein J. Angiographic and clinical characteristics of type 1 versus type 2 perioperative myocardial infarction. Catheter Cardiovasc Interv. 2013 Oct 1;82 (4):622–8.
  16. Smith SW, Pearce LA, Murakami MM, Apple FS. Diagnosis of type I versus type II myocardial infarction in emergency department patients with ischemic symptoms. Ann Emerg Med. 2011 Oct;58 (4):S211–2.
  17. Saaby L, Poulsen TS, Diederichsen AC, Hosbond S, Larsen TB, Schmidt H et al. Mortality rate in type 2 myocardial infarction: observations from an unselected hospital cohort. Am J Med. 2014 Apr;127 (4):295–302.
  18. Di Pasquale P, Lo Verso P, Bucca V, Cannizzaro S, Scalzo S, Maringhini G et al. Effects of trimetazidine administration before thrombolysis in patients with anterior myocardial infarction: short-term and long-term results. Cardiovasc Drugs Ther. 1999 Sep;13 (5):423–8.
  19. Papadopoulos CL, Kanonidis IE, Kotridis PS, Papayannis IL, Savatis SC, Missopoulou-Kokka AI et al. The effect of trimetazidine on reperfusion arrhythmias in acute myocardial infarction. Int J Cardiol. 1996 Jul 26;55 (2):137–42.
  20. Shehata M. Cardioprotective effects of oral trimetazidine in diabetic patients with anterior wall myocardial infarction treated with thrombolysis. Cardiol Res. 2014 Apr;5 (2):58–67.
  21. Kim JS, Kim CH, Chun KJ, Kim JH, Park YH, Kim J et al. Effects of trimetazidine in patients with acute myocardial infarction: data from the Korean Acute Myocardial Infarction Registry. Clin Res Cardiol. 2013 Dec;102 (12):915–22.
  22. Iyengar SS, Rosano GM. Effect of antianginal drugs in stable angina on predicted mortality risk after surviving a myocardial infarction. A preliminary study (METRO). Am J Cardiovasc Drugs. 2009;9 (5):293–7.
  23. Morrow DA, Scirica BM, Karwatowska-Prokopczuk E, Murphy SA, Budaj A, Varshavsky S et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-st-elevation acute coronary syndromes. The MERLIN-TIMI 36 randomized trial. JAMA. 2007 Apr 25;297 (16):1775–83.
Zharsky S.L. Type 2 myocardial infarction: Solved and unsolved issues. Russian Heart Journal. 2016;15 (6):404–409

To access this material please log in or register

Register Authorize
Ru En